Efficacy and safety of diphereline 11.25 mg, microrelin 11.25 mg, and microrelin 3.75 mg in premenopausal patients with breast cancer: a non-inferiority randomized clinical trial

• Published in: BMC cancer 2023-11, Vol.23 (1), p.1-1093, Article 1093
• Main Authors: Najafi, Safa, Ansari, Maryam, Omidi, Zahra, Olfatbakhsh, Asiie, Moghadam, Shiva, Hashemi, Esmat-o-Sadat, Najafi, Niki, Haghighat, Shahpar
• Format: Article
• Language: English
• Subjects: 17β-Estradiol; Breast cancer; Cancer research; Cancer therapies; Diphereline; Drug dosages; Endocrine therapy; Estrogens; Follicle-stimulating hormone; Gonadotropin-releasing hormone; Gonadotropin-releasing hormone agonist; Gonadotropins; Iran; Medical prognosis; Medical research; Menopause; Menstruation; Microrelin; Ovaries; Pharmaceutical industry; Pituitary (anterior); Pituitary gland; Questionnaires; Serum levels; Side effects; Statistical analysis
• ISSN: 1471-2407; 1471-2407
• DOI: 10.1186/s12885-023-11614-7

Background Diphereline is a Gonadotropin-Releasing Hormone agonist commonly used in patients with breast cancer. This study aimed to compare the efficacy and safety of one-month and three-month Microrelin injections produced by Homa Pharmed Company with three-month Diphereline injections manufactured by IPSEN, France. Methods The study was a non-inferiority randomized clinical trial conducted between 2019 and 2023 on premenopausal women candidates for endocrine therapy. The participants were randomly assigned in blocks of six to one of three groups named A (Diphereline 11.25 mg), B (Microrelin 11.25 mg), and C (Microrelin 3.75 mg). The participants' menopausal symptoms, estradiol, and FSH serum levels were recorded in three-month intervals for one year. The efficacy of each medication and its side effects were compared among the three groups by statistical analysis during the one-year follow-up. Results The study included 133 patients with breast cancer. A decreasing trend in the serum levels of FSH and estradiol and an increasing trend of menopausal symptoms were recorded during the study. No specific side effects leading to drug disruption, hospitalization, or exclusion from the study were observed. Adjusting the effect of study group and time showed no significant changes in estradiol levels between groups B (p = 0.506) and C (p = 0.607) and group A. Also, serum FSH changes between groups B (p = 0.132) and C (p = 0.104) compared to group A were not significant. Moreover, the menopausal symptoms during the one-year follow-up did not significantly increase in group B (p = 0.108) and C (p = 0.113) compared to group A. Conclusions It can be concluded that injections of both Microrelin 11.25 mg and 3.75 mg, produced by Homa Pharmed, Iran, are non-inferior in terms of effectiveness and incidence of menopausal symptoms compared to Diphereline, manufactured by IPSEN, France. Trial registration IRCT.ir, IRCT20201227049847N1; Registered on 09/01/2021. Keywords: Breast cancer, Diphereline, Microrelin, Gonadotropin-releasing hormone agonist, Iran